Find disease awareness content and relevant supporting materials
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Areas covered: This article reviews the clinical efficacy and safety of oral and intravenous lasmiditan as a possible acute migraine treatment. We analyze all currently available results in Phase I to III studies.
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
Objective: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
he primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder.